Twendee X Ameliorates Phosphorylated Tau, α-Synuclein and Neurovascular Dysfunction in Alzheimer's Disease Transgenic Mice With Chronic Cerebral Hypoperfusion by Liu, Xia et al.
1 
 
Twendee X ameliorates phosphorylated tau, α-synuclein and 
neurovascular dysfunction in Alzheimer’s disease transgenic 
mice with chronic cerebral hypoperfusion 
 
Xia Liu, Toru Yamashita, Jingwei Shang, Xiaowen Shi, Ryuta Morihara, Yong Huang, 
Kota Sato, Mami Takemoto, Nozomi Hishikawa, Yasuyuki Ohta, and Koji Abe 
 
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical 
Sciences, Okayama University, 2-5-1 Shikatacho, Kitaku, Okayama 700-8558, Japan 
 
Running headline: Neuroprotective effect of Twendee X. 
 
Keywords: Alzheimer’s disease, APP23 mice, chronic cerebral hypoperfusion, phosphorylated 
tau, α-synuclein, neurovascular dysfunction. 
 
Corresponding author: Prof. Koji Abe, Department of Neurology, Okayama 
University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 
Shikata-cho, Okayama 700-8558, Japan. E-mail: pggx277x@hotmail.com 
 
Abbreviations used: AD, Alzheimer’s disease; Aβ, amyloid-β; BCCAs, bilateral common carotid arteries; BDNF, 
brain-derived neurotrophic factor; BSA, bovine serum albumin; CCH, chronic cerebral hypoperfusion; CTX, cortex; 
DG, dentate gyrus; GFAP, glial fibrillary acidic protein; HI, hippocampus; LEL, Lycopersicon esculentum lectin; 
M, months; NAGO, N-acetylglucosamine oligomers; NVU, neurovascular unit; PBS, phosphate-buffered saline; 
PDGFRβ, platelet-derived growth factor receptor β; PFA, paraformaldehyde; TH, thalamus; TrkB, tropomyosin 





Background: The pathological impact of chronic cerebral hypoperfusion (CCH) on 
Alzheimer’s disease (AD) is still poorly understood. In the present study, we investigated the 
role of CCH on an AD mouse model in phosphorylated tau and α-synuclein pathology, 
neurovascular unit, cerebrovascular remodeling, and neurovascular trophic coupling. Moreover, 
examined protective effect of a new antioxidant Twendee X (TwX). 
Methods: APP23 mice were implanted to bilateral common carotid arteries stenosis with 
ameroid constrictors to gradually decrease the cerebral blood flow. The effects of the 
administration of TwX were evaluated by immunohistochemical analysis and 
Immunofluorescent histochemistry. 
Results: The present study revealed that the expressions of phospho-tau and phospho-α-
synuclein were significantly increased in the APP23 + CCH mice group as compared with wild 
type and APP23 mice groups (*p < 0.05 and **p < 0.01 vs WT; # p < 0.05 and ## p < 0.01 vs 
APP23). In addition, CCH significantly exacerbated MMP-9 activation relating to blood-brain 
barrier destruction (**p < 0.01 vs WT; # p < 0.05 and ## p < 0.01 vs APP23), enhanced 
neurovascular remodeling, and impaired a neurovascular trophic coupling in the vascular 
endothelial BDNF expression of the APP23 + CCH group. TwX treatment (20 mg/kg/d, from 
4.5 to 12 months) significantly reduced tau and α-synuclein pathologies, ameliorated 
neurovascular dysfunction compared with APP23 + CCH group. 
Conclusions: Our findings indicate that administration of a new anti-oxidative mixture TwX 
substantially reduced the above neuropathologic abnormalities, suggesting a potential 




Alzheimer’s disease (AD) represents approximately 69% of all dementia among the 
people older than 75 years, 1 which is associated with amyloid-β (Aβ) plaques, neurofibrillary 
tangles, and white matter abnormality. 2-3 Aβ plaques and neurofibrillary tangles consist mostly 
of Aβ and tau proteins. 4 In addition, up to 50% of AD patients exhibit significant Lewy bodies 
pathology, 5-7 in which α-synuclein is the primary component of Lewy bodies. 8 
 The dysfunction of the neurovascular unit (NVU) is regarded as an early event in AD, 9 
and chronic cerebral hypoperfusion (CCH) is defined as one of the major mechanisms of 
cerebral vascular disorders. 3,10 Our recent studies showed CCH strongly enhanced AD 
pathology in mice. 11-12   
Twendee X (TwX) is a new multiple antioxidant mixture that contains ingredients such as 
coenzyme Q10, ascorbic acid, L-glutamine and cystine. Our previous study showed the 
neuroprotective effects of TwX in an acute cerebral ischemia mice model by reducing ischemic 
infarct and attenuating both oxidative stress and inflammation. 13  
Therefore, the present study aimed to investigate a possible therapeutic effect of TwX on 
tau and α-synuclein pathology, damage of NVU and neurovascular trophic coupling in an AD 
mouse model with CCH. 
 
Materials and methods 
Animals 
All animal experimental procedures were approved by the guidelines of the Animal 
Committee of the Graduate School of Medicine and Dentistry of Okayama University (OKU-
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2014-095). All experiments were carried out on APP23 mice which overexpress human 
APP751 isoform carrying the Swedish double mutation (KM670/671NL) 14 and wild type (non-
transgenic) littermates. APP23 male mice were obtained from Dr. Takashi Saito (RIKEN Brain 
Science Institute, Saitama, Japan) and maintained as hemizygotes by mating APP23 male mice 
with C57BL/6J female mice (CLEA Japan, Tokyo, Japan). At 4 months (M) of age (before 
surgery), the body weights of male mice were 29.2 grams (g) to 32.1 g, the body weights of 
female mice were 20.5 g to 22.9 g, and there was no significant difference between APP23 mice 
and wild type littermates. The offspring were genotyped using a PCR assay with DNA obtained 
from tail tissue samples. All mice were housed in 12:12-hour light-dark cycle with controlled 
temperature and free access to food and water.  
 
Experimental Groups and Drug Treatments 
Four experimental groups of mice were designed in the present study: wild type mice (WT 
+ sham surgery, male n = 5, female n= 5), APP23 group (APP23 + sham surgery, male n = 5, 
female n= 5), CCH group (APP23 + CCH, male n = 7, female n= 5) and TwX group (APP23 + 
CCH + TwX, male n = 6, female n= 7). For the mice in CCH and TwX groups, ameriod 
constrictors with an inner diameter of 0.75mm and an open gap of 0.5mm (Research 
Instruments NW, Lebanon, OR, USA) were applied to the bilateral common carotid arteries 
(BCCAs) at 4 M of age as described previously. 11-12  
TwX is a mixture antioxidants, 13 which contains ingredients as follows: coenzyme Q10 
(3.6 wt%; AQUA Q10 P40-NF, Nissin Pharmaceutical, Tokyo, Japan), niacin amid (0.7 wt%), 
L-cystine (18.2 wt%), ascorbic acid (34.2 wt%), succinic acid (3.6 wt%), fumaric acid (3.6 
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wt%), L-glutamine (34.6 wt%), and riboflavin (1.5 wt%; Bislase inj, Toa Eiyo, Tokyo, Japan). 
The mice in TwX group began to receive TwX (20 mg/kg per day) by oral gavage once daily 
from 4.5 M of age until sacrifice. This dose of TwX was decided according to a previous study 
which showing its neuroprotective effectiveness in transient middle cerebral artery occlusion 
mice. 13 The present study is a part of whole project in this mice model mainly focusing on 
abnormal protein deposition, NVU and neurovascular trophic coupling. 
 
Tissue preparation  
The mice aged 12 M were deeply anesthetized with pentobarbital (40 mg/kg) and perfused 
transcardially with 20ml chilled phosphate-buffered saline (PBS, pH 7.4), followed by cold 4% 
paraformaldehyde (PFA). The brains were removed and post-fixed in 4% PFA overnight, then 
transferred into 10, 20 and 30% (wt/vol) sucrose in PBS for 24h, respectively. They were then 
sectioned in to coronal brain sections (20 μm) by using a cryostat at -20°C and mounted on 
silane-coated glass slides.  
 
Immunohistochemical analysis 
After incubation in 0.3% hydrogen peroxide/methanol followed by 5% bovine serum 
albumin (BSA), the sections were incubated overnight at 4°C with the following primary 
antibody: mouse anti-tau antibody (1:500, Cell Signaling Technology, Beverly, MA, USA), 
mouse anti-phospho-tau antibody (1:100, Thermo Fisher Scientific, Rockford, IL, USA), 
mouse anti-phospho-α-synuclein antibody (1:500, Wako, Osaka, Japan) and rabbit anti-MMP-
9 antibody (1:100, Millipore Corporation, Billerica, MA, USA). Sections were washed with 
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PBS, then incubated with suitable biotinylated secondary antibodies (1:500; Vector 
Laboratories) at room temperature for 2 h. After washed with PBS, sections were treated with 
the avidin–biotin–peroxidase complex (VECTASTAIN Elite ABC Kit; Vector Laboratories) for 
30 min and visualized with 3, 3′-diaminobenzidine (DAB). For semiquantitative analysis of tau, 
phospho-tau, phospho-α-synuclein and MMP-9 staining, 3 separated sections per brain from 3 
levels (-1.3, -1.8 and -2.3 mm posterior to the bregma), and 5 random selected regions from 
cerebral cortex (CTX), hippocampus (HI), and thalamus (TH) were captured at × 200 
magnification with a light microscope (Olympus BX-51, Tokyo, Japan). The pixel intensity was 
measured using ImageJ software by 2 individuals who were blind to experimental group, and 
then calculated as a percentage of WT group. 
 
Immunofluorescent histochemistry 
To determine the remodeling of NVU and changes of neurovascular trophic coupling, 
double immunofluorescence histochemistry were performed for collagen IV plus glial fibrillary 
acidic protein (GFAP), brain-derived neurotrophic factor (BDNF) plus N-acetylglucosamine 
oligomers (NAGO), BDNF plus tropomyosin receptor kinase B (TrkB), BDNF plus GFAP and 
BDNF plus platelet-derived growth factor receptor β (PDGFRβ). Lycopersicon esculentum 
lectin (LEL) is a glycoprotein with specific affinity for NAGO, which is expressed in mature 
vascular endothelial cells. 15 Primary antibodies were used as follows: rabbit anti-collagen IV 
antibody (1:500, Abcam, Cambridge, MA, USA), goat anti-GFAP antibody (1:1000, R&D 
Systems, Minneapolis, MN, USA), sheep anti-BDNF antibody (1:100, Abcam), biotinylated 
LEL (1:200, Vector Laboratories, Burlingame, CA, USA), rabbit anti-TrkB antibody (1:200, 
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Santa Cruz Biotechnology, Santa Cruz, CA, USA), and rabbit anti-PDGFRβ antibody (1:100, 
Cell Signaling Technology). After washing, sections were incubated with fluorescent secondary 
antibody, and then scanned with a confocal microscope equipped with an argon and HeNe1 
laser (LSM-780; Zeiss, Jena, Germany). 
 
Statistical analysis 
All data were expressed as mean ± SD. Statistical comparison was performed using one-
way ANOVA analysis followed by Tukey-Kramer test as a post hoc test. Statistically 
significance was defined as p < 0.05. 
 
Results 
Changes of tau pathology and α-synuclein phosphorylation after CCH 
As shown in Fig. 1, there was no significant difference between 4 groups in total-tau 
expressions (Fig. 1A and 1B). In contrast, 3 APP23 groups displayed significant increases of 
phospho-tau (AT8) immunoreactivity than WT group in the CTX with the highest expression 
in CCH group, which was recovered by TwX treatment (Fig. 1A and 1C, *p < 0.05 and **p < 
0.01 vs WT; # p < 0.05 vs APP23; $p < 0.05 vs CCH). Similar tendencies were observed in 3 
APP23 groups in phospho-tau of CA1 (Fig. 1A and 1C).  
The expression of phospho-α-synuclein significantly increased in 3 APP23 groups in CTX, 
CA1, dentate gyrus (DG) and TH, especially in CCH group (Fig. 2A and 2B). Compared with 
CCH group, the administration of TwX greatly decreased such accumulation of phospho-α-
synuclein in both CTX and TH (Fig. 2A and 2B, *p < 0.05 and **p < 0.01 vs WT; # p < 0.05 
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and ## p < 0.01 vs APP23; $p < 0.05 and $$p < 0.01 vs CCH). 
 
MMP-9 and NVU remodeling after CCH 
The MMP-9 was only slightly detected in neurons of CTX and blood vessel wall of TH 
(Fig. 3A) in WT mice, which was significantly upregulated in 3 APP23 groups especially in 
CCH group and was greatly recovered by TwX treatment (Fig. 2A and 2B, **p < 0.01 vs WT; # 
p < 0.05 and ## p < 0.01 vs APP23; $p < 0.05 and $$p < 0.01 vs CCH). 
Double immunofluorescent analysis of collagen IV/GFAP showed morphological changes 
of collagen IV and astrocytes in HI and TH of 3 APP23 groups (Fig. 4A and 4B). The changes 
were much enhanced in TH of APP23 + CCH groups, which was ameliorated by TwX 
treatments (Fig. 4B). 
 
Changes of neurovascular trophic coupling after CCH 
BDNF was immunopositive in vascular endothelial cells (Fig. 5A), neurons (Fig. 5B), 
astrocytes (Fig. 6A) and pericytes (Fig. 6B), but which was significantly decreased in 3 APP23 
groups compared with WT group with a remarkable decline in CCH group (Fig. 5 and 6). TwX 
treatment showed a significant restoration of BDNF expression in all cell types compared with 
CCH group (Fig. 5 and 6). 
 
Discussion 
In present study, we demonstrated that the administration of antioxidative mixture TwX 
attenuated tau hyperphosphorylation (Fig. 1) and phospho-α-synuclein deposition (Fig. 2), 
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decreased MMP-9 activation (Fig. 3), alleviated NVU remodeling (Fig. 4), and ameliorated 
neurovascular trophic coupling damage (Figs. 5-6) in the CCH model of APP23 mice. Although 
numerous studies indicated that Aβ, tau, and α-synuclein play synergistical roles in AD 
pathogenesis, 4, 16-17 a pathological impact of CCH is still poorly understood on these protein 
accumulations. Here our results newly found that CCH significantly promoted tau 
hyperphosphorylation and α-synuclein accumulation in AD mice, which were ameliorated by 
the administration of TwX (Figs. 1-2).  
APP23 mice are characterized by increasing Aβ deposition in the brain from 6 M of age, 
tau hyperphosphorylation could also be detected at 6 M. 14 In our previous studies, cognitive 
deficit, Aβ pathology, and neurovascular dysfunction had become remarkable at 12 M of age. 
11-12 Thus we studied the effect of TwX at 12 M of age in this model in the present study.  
After implanting the ameriod constrictors, the mice cerebral blood flow, which was 
demonstrated by a laser-Doppler flowmeter, showed a gradually decreased and reached a steady 
status until 28 d.12, 30 In another paper, we showed the effect of TwX on improving cognitive 
deficit, reducing primary AD pathology with inhibiting inflammatory and oxidative stresses. 30  
NVU is structurally composed of vascular endothelial cells, vascular smooth muscle cells, 
astrocytes, and perivascular neurons, 9 which functionally serves the basis of neurovascular 
coupling. 18-20 The dysfunction of NVU impaired CBF regulation and BBB transport, leading 
to the impairment of Aβ clearance to enhance AD pathology. 21-22 The present APP23 + CCH 
group showed the higher MMP-9 expression than the simple APP23 group, and exacerbated 
BBB leakage and abnormal neurovascular remodeling, which were suppressed by TwX 
treatment (Figs. 3-4).  
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BDNF is a member of the neurotrophin family, 23 which plays important role in neuronal 
growth and survival as well as synaptic plasticity in both animal models and AD patients. 24-25 
Therefore, the reduction of BDNF expression of AD and MCI patients is related to cognitive 
impairment. 26-29 The present results indicated that CCH decreased the BDNF expression in 
endothelium cells, neuronal cells, astrocytes and pericytes (Figs. 5-6), which was recovered by 
TwX to protect against CCH injury on neurovascular coupling in APP23 mice (Figs. 5-6). 
In conclusion, the present study newly revealed that CCH enhanced tau 
hyperphosphorylation and phospho-α-synuclein levels, exacerbated the NVU dysfunction and 
neurovascular coupling in APP23 mice, and TwX treatment remarkably ameliorated such 
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Fig. 1) (A) Single immunohistochemistry of total-tau and phospho-tau (p-tau, AT8) changes in 
cerebral cortex (CTX) and hippocampal CA1 of AD mice model with chronic cerebral 
hypoperfusion (CCH). (B) Quantitative analysis of total-tau and (C) p-tau (*p < 0.05 and **p < 
0.01 vs WT; # p < 0.05 vs APP23; $p < 0.05 vs CCH. Scale bar = 50 μm). 
 
Fig. 2) (A) Single immunohistochemistry of phosphorylated α-synuclein expression in CTX, 
hippocampal CA1 and dentate gyrus (DG), and thalamus (TH) of AD mice model with CCH. 
(B) Quantitative analysis of phosphorylated α-synuclein (*p < 0.05 and **p < 0.01 vs WT; # p < 
0.05 and ## p < 0.01 vs APP23; $p < 0.05 and $$p < 0.01 vs CCH. Scale bar = 50 μm). 
 
Fig. 3) (A) Single immunohistochemistry of MMP-9 in the parenchyma and blood vessels of 
CTX and TH of AD mice with CCH. (B) Quantitative analysis of MMP-9 (**p < 0.01 vs WT; # 
p < 0.05 and ## p < 0.01 vs APP23; $p < 0.05 and $$p < 0.01 vs CCH. Scale bar = 50 μm). 
  
Fig. 4) Double immunofluorescent analysis of collagen IV plus GFAP in the hippocampus (HI) 
(A) and TH (B). Note the significant enlarged vessels with morphological changes of the 
collagen IV and astrocyte in APP23+CCH group, especially in TH (Scale bar = 50 μm). 
 
Fig. 5) Double immunofluorescent analysis of BDNF plus NAGO (A) or TrkB (B) in CTX. 
Note the significantly decreased BDNF immunoreactivity in endothelium cells and neurons of 
3 APP23 groups, especially in APP23+CCH group (Scale bar = 50 μm). 
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Fig. 6) Double immunofluorescent analysis of BDNF plus GFAP (A) or PDGFRβ (B) in CTX. 
Note the significantly decreased BDNF immunoreactivity in astrocytes and pericytes of 3 
APP23 groups, especially in APP23+CCH group (Scale bar = 50 μm).  
